VOR AI

Vor Bio is a clinical-stage biotechnology company focused on autoimmune diseases. After previously operating as a cell and gene therapy company in hematologic cancers, the company reoriented in 2025 around telitacicept, a dual BAFF/APRIL-targeting TACI-Fc fusion protein licensed ex-China from RemeGen. Vor is advancing telitacicept through global Phase 3 development, with current lead indications including myasthenia gravis and Sjögren’s disease. The drug is already commercially validated in China across several autoimmune indications, while Vor is pursuing ex-China development and potential commercialization. The company is publicly traded on Nasdaq and is headquartered in Cambridge, Massachusetts.